The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to ...

Regeneron Pharmaceuticals (Nasdaq: REGN) today announced that the European Commission (EC) has granted conditional marketing ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie ...

Regeneron’s bispecific antibody linvoseltamab, now branded as Lynozyfic, has received conditional approval from the European ...